Variability in drug metabolizing enzyme activity in HIV-infected patients

European Journal of Clinical Pharmacology

Volumn 66, Issue 5, 2010, Pages 475-485

  Jones, Amanda E ^a   Brown, Kevin C ^a   Werner, Rebecca E ^b   Gotzkowsky, Karl ^a   Gaedigk, Andrea ^c   Blake, Mike ^c   Hein, David W ^d   Van Der Horst, Charles ^b   Kashuba, Angela D M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c CHILDREN S MERCY HOSPITAL   (United States)

^d University of Louisville School of Medicine   (United States)

Author keywords

Cytokines; Drug metabolizing enzymes; HIV; Metabolism

Indexed keywords

5 ACETAMIDO 6 FORMYLAMINO 3 METHYLURACIL; ARYLAMINE ACETYLTRANSFERASE; CAFFEINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; DEXTROMETHORPHAN; DEXTRORPHAN; DIDANOSINE; HYDROXYUREA; INTERLEUKIN 6; LAMIVUDINE PLUS ZIDOVUDINE; MIDAZOLAM; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA; XANTHINE OXIDASE; CYTOCHROME P450; NAT2 PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; PHENOTYPE; PRIORITY JOURNAL; SEX DIFFERENCE; URINALYSIS; BLOOD; METABOLISM;

ADULT; ARYLAMINE N-ACETYLTRANSFERASE; CAFFEINE; CYTOCHROME P-450 ENZYME SYSTEM; DEXTROMETHORPHAN; FEMALE; HIV INFECTIONS; HUMANS; INTERLEUKIN-6; MALE; MIDAZOLAM; PHENOTYPE; TUMOR NECROSIS FACTOR-ALPHA; XANTHINE OXIDASE;

EID: 77954461644     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-009-0777-6     Document Type: Article

References (56)

1. Guengerich FP (2003) Cytochromes P450, drugs, and diseases. Mol Interv 3:194-202
2. Flockhart DA, Oesterheld JR (2000) Cytochrome P450-mediated drug interactions. Child Adolesc Psychiatr Clin N Am 9:43-76
3. Cuyue T, Jiunn LH, Anthony LHY (2005) Metabolism-based drug-drug interactions what determines individual variability in cytochrome P450 induction? Drug Metab Dispo 33:603-613
4. Morgan ET (2001) Regulation of cytochrome P450 by inflammatory mediators: why and how? DMD 29:207-212
5. Aitken AE, Richardson TA, Morgan ET (2006) Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol 46:123-149
6. Morgan ET (1997) Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev 29(4):1129-1188
7. O'Neil WM, Gilfix BM, DiGirolamo A, Tsoukas CM, Wainer IW (1997) N-acetylation among HIV-positive patients and patients with AIDS: when is fast, fast and slow, slow? Clin Pharmacol Ther 62(3):261-271
8. O'Neil WM, Gilfix BM, Markoglou N, DiGirolamo A, Tsoukas CM, Wainer IW (2000) Genotype and phenotype of cytochrome P450 2D6 in human immunodeficiency virus-positive patients with acquired immunodeficiency syndrome. Eur J Clin Pharmacol 56:231-240
9. Battelli MG, Musiani S, Valgimigli M, Gramantieri L, Tomassoni F, Bolondi L, Stirpe F (2001) Serum xanthine oxidase in human liver disease. Am J Gastroenterol 96(4):1194-1199
10. Zhang C, Xu X, Potter BJ, Wang W, Kuo L, Michael L, Bagby GJ, Chillian WM (2006) TNF-alpha contributes to endothelial dysfunction in ischemia/reperfusion injury. Arterioscler Thromb Vasc Biol 26(3):475-480
11. Roulston A, Lin R, Beauparlant P, Wainberg MA, Hiscott J (1996) Regulation of human immunodeficiency virus type I and cytokine gene expression in myeloid cells by NF-kappa B/Rel transcription factors. Microbiol Rev 59:481-505
12. Poli G, Biswas P, Fauci A (1994) Interferons in the pathogenesis and treatment of human immunodeficiency virus infection. Antiviral Res 24:221-233 (Pubitemid 24228876)
13. DiPiro J (1997) Cytokine networks with infection: mycobacterial infection, leishmaniasis, human immunodeficiency virus infection, and sepsis. Pharmacotherapy 17:205-223
14. Bernemann M, Verhael J, Peterson P (1997) Macrophage, cytokines, and HIV. J Lab Clin Med 129:10-16
15. Montoya CJ, Rugeles MT, Landay AL (2006) Innate immune defenses in HIV-1 infection: prospects for a novel immune therapy. Expert Rev Anti Infect Ther 4(5):767-1180
16. Centers for Disease Control and Prevention. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR. Updated 3 November 2008. Available at http://www.aidsinfo.nih.gov/ Accessed 30 June 2009
17. Watkins PB (1994) Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4(4):171-184
18. Streetman DS, Bertino JS Jr, Nafziger AN (2000) Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10 (3):187-216
19. Huang SM, Strong JM, Zhang L et al (2008) New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 48(6):662-670
20. Huang SM, Temple R, Throckmorton DC et al (2007) Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 81(2):298-304
21. Kashuba ADM, Bertino JS, Kulawy RML, RW BDJ, Nafziger AN (1998) Quantification of 3-month intraindividual variability, and the influence of sex and menstrual cycle phase, on CYP3A as measured by phenotyping with intravenous midazolam. Clin Pharmacol Ther 64:269-277
22. Kashuba AD, Bertino JS Jr, Kearns GL, Leeder JS, James AW, Gotschall R, Nafziger AN (1998) Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidases activity determined with caffeine phenotyping. Clin Pharmacol Ther 63(5):540-551
23. Kashuba ADM, Nafziger AN, Kearns GL, Leeder JS, Shirey CS, Gotschall R, Gaedigk A, Bertino JS (1998) Quantification of intraindividual variability, and the influence of sex and menstrual cycle phase, on CYP2D6 as measured by dextromethorphan phenotyping. Pharmacogenetics 8:403-410
24. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS (2008) The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 83:234-242
25. Doll MA, Hein DW (2001) Comprehensive human NAT2 genotype method using single nucleotide polymorphism-specific polymerase chain reaction primers and fluorogenic probes. Anal Biochem 288:106-108
26. Hein DW (2006) N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene 25:1649-1658
27. Yeh GC, Tao PL, Ho HO, Lee YJ, Chen JY, Sheu MT (2003) Analysis of pharmacokinetic parameters for assessment of dextromethorphan metabolic phenotypes. J Biomed Sci 10:552-564
28. Woolridge H, Williams J, Cronin A et al (2004) CYP1A2 in a smoking and non-smoking population; correlation of urinary and salivary phenotypic ratios. Drug Metabol Drug Interact 20:247-261
29. Haas CE, Kaufman DC, Jones CE, Burstein AH, Reiss W (2003) Cytochrome P450 3A4 activity after surgical stress. Crit Care Med 31(5):1338-1346
30. Trenholme GM, Williams RL, Rieckmann KH, Frischer H, Carson PE (1976) Quinine disposition during malaria and during induced fever. Clin Pharmacol Ther 10(4):459-467
31. Sonne J, Dossing M, Loft S, Andreasen PB (1985) Antipyrine clearance in pneumonia. Clin Pharmacol Ther 37(6):701-704
32. Chen YL, Le Vraux V, Leneveu A, Dreyfus F, Stheneur A, Florentin I, De Sousa M, Giroud JP, Flouvat B, Chauvelot-Moachon I (1994) Acute-phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics. Clin Pharmacol Ther 55(6):649-660
33. Slain D, Pakyz A, Israel DS, Monroe S, Polk RE (2000) Variability in activity of hepatic CYP3A4 in patients infected with HIV. Pharmacotherapy 20(8):898-907
34. Roy JN, Lajoie J, Zijenah LS et al (2005) CYP3A5 genetic polymorphism in different ethnic populations. Drug Metab Dispos 33(7):884-887
35. Gaedigk A, Bradford LD, Marcucci KA, Leeder JS (2002) Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther 72(1):76-89
36. Gaedigk A, Bhathena A, Ndjountche L, Pearce RE, Abdel-Rahman SM, Alander SW, Bradford LD, Rogan PK, Leeder JS (2005) Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans. Pharmacogenetics 5(3):173-182
37. Raimundo S, Fischer J, Eichelbaum M, Griese EU, Schwab M, Zanger UM (2000) Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics 10(7):577-581
38. Raimundo S, Toscano C, Klein K, Fischer J, Griese EU, Eichelbaum M, Schwab M, Zanger UM (2004) A novel intronic mutation, 2988G >A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin Pharmacol Ther 76(2):128-138
39. Leathart J, London SJ, Stweard A, Adams JD, Idle JR, Daly AK (1998) CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics 8:529-541
40. Griese EU, Asante-Poku S, Ofori-Adjei D, Mikus G, Eichelbaum M (1999) Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population. Pharmacogenetics 9(6):715-723
41. U.S National Institute of Mental Health (2002) Depression and HIV/AIDS. http://www.thebody.com/content/art6295.html#ptdep2Accessed 29 June 2008
42. Chang KC, Bell TD, Lauer BA, Chai H (1978) Altered theophylline pharmacokinetics during acute viral respiratory illness. Lancet 1(8074):1132-1133
43. Dong SX, Ping ZZ, Xiao WZ, Shu CC, Bartoli A, Gatti G, D'Urso S, Perucca E (1998) Effect of active and passive cigarette smoking on CYP1A2-mediated phenacetin disposition in Chinese subjects. Ther Drug Monit 20(4):371-375
44. Matsunga SK, Plezia PM, Karol MD, Katz MD, Camilli AE, Benowitz NL (1989) Effects of passive smoking on theophylline clearance. Clin Pharmacol Ther 46:399-407
45. Lee BL, Wong D, Benowitz NL, Sullam PM (1993) Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clin Pharmacol Ther 53(5):529-535
46. Delomenie C, Grant DM, Mathelier-Fusade P, Jacomet C, Leynadier F, Jacqz-Aigrain E, Rozenbaum W, Krishnamoorthy R, Dupret JM (1994) N-acetylation genotype and risk of severe reactions to sulphonamides in AIDS patients. Br J Clin Pharmacol 38:581-582
47. Renton KW, Knickle LC (1990) Regulation of hepatic cytochrome P-450 during infectious disease. Can J Physiol Pharmacol 68:777-781
48. Adamson GM, Billings RE (1994) The role of xanthine oxidase in oxidative damage caused by cytokines in cultured mouse hepatocytes. Life Sci 55(22):1071-1079
49. Moochhala SM, Renton KW (1991) A role of xanthine oxidase in the loss of cytochrome P-450 evoked by interferon. Can J Physiol Pharmacol 69(7):944-950
50. Mannering GJ, Deloria LB, Abbott V (1988) Role of xanthine oxidase in the interferon-mediated depression of the hepatic cytochrome P-450 system in mice. Cancer Res 48(8):2107-2112
51. Cribb AE, Renton KW (1993) Dissociation of xanthine oxidase induction and cytochrome P450 depression during interferon induction in the rat. Biochem Pharmacol 46(11):2114-2117
52. Tilton JC, Johnson AJ, Luskin MR, Manion MM, Yang J, Adelsberger JW, Lempicki RA, Hallahan CW, McLaughlin M, Mican JW, Metcalf JA, Iyasere C, Connors M (2006) Diminished production of monocyte proinflammatory cytokines during human immunodeficiency virus viremia is mediated by type I interferons. J Virol 80(24):11486-11497
53. Muntane-Relat J, Ourlin JC, Domergue J, Maurel P (1995) Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2 and CYP3A4 in human hepatocytes in primary culture. Hepatology 22:1143-1153
54. Jover R, Bort R, Gomez-Lechon MJ, Castell JV (2002) Downregulation of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involved. FASEB J 16(13):1799-1801
55. Sarlis NJ, Gourgiotis L (2005) Hormonal effects on drug metabolism through the CYP system: perspectives on their potential significance in the era of pharmacogenomics. Curr Drug Targets Immune Endocr Metabol Disord 5(4):439-448
56. Sunman JA, Hawke RL, LeCluyse EL, Kashuba AD (2004) Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. Drug Metab Dispos 32(3):359-363